Ubrelvy (ubrogepant)

Eli Lilly hit by migraine drug launch slowdown, but rivals jump

As the dust settles around pharma’s second-quarter financial readouts, we check in on how the new and increasingly crowded migraine market is looking.

Ben Adams Aug 5, 2022 11:58am